LEADER 01761nam  2200433   450 
001 9910711623503321
005 20181214191436.0
035   $a(CKB)5470000002485829
035   $a(OCoLC)1078951640
035   $a(EXLCZ)995470000002485829
100   $a20181214d2018      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aEpiPen price increases $ehow regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY)
210  1$aWashington :$cU.S. Government Publishing Office,$d2018.
215   $a1 online resource (iii, 43 pages) $cillustrations
225 1 $aS. hrg. ;$v114-805
320   $aIncludes bibliographical references.
517   $aEpiPen price increases 
606   $aPrescription pricing$zUnited States
606   $aDrugs$xLaw and legislation$zUnited States
606   $aPharmaceutical industry$zUnited States
606   $aCompetition$zUnited States
606   $aDrug delivery devices$xPrices$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aPrescription pricing
615  0$aDrugs$xLaw and legislation
615  0$aPharmaceutical industry
615  0$aCompetition
615  0$aDrug delivery devices$xPrices
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910711623503321
996   $aEpiPen price increases$93528170
997   $aUNINA